---
schema_version: "secwatch.filing_event.v1"
accession: "0001728117-25-000082"
form_type: "8-K"
ticker: "GOSS"
cik: "0001728117"
company_name: "Gossamer Bio, Inc."
filed_at: "2025-11-05T23:59:59+00:00"
generated_at: "2026-05-17T00:20:24.067508+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Gossamer Bio Q3 net loss $48.2M; PROSERA topline due Feb 2026

## Summary
- Net loss of $48.2M ($0.21 per share) vs $30.8M loss a year ago; revenue from Chiesi collab $13.3M.
- Cash, cash equivalents and marketable securities $180.2M; sufficient to fund ops into 2027.
- PROSERA Phase 3 PAH study enrollment complete (390 pts); topline results expected February 2026.
- First site activated for SERANATA Phase 3 PH-ILD study; targeting enrollment of ~480 patients.
- Strategic option agreement to acquire Respira via 1.5M shares; no new trials expected before 2027.

## SEC filing metadata
- accession: 0001728117-25-000082
- form_type: 8-K
- ticker: GOSS
- cik: 0001728117
- company_name: Gossamer Bio, Inc.
- filed_at: 2025-11-05T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1728117/000172811725000082/0001728117-25-000082-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1728117/000172811725000082/goss-20251105.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001728117-25-000082
- JSON: https://secwatch.observer/filing/0001728117-25-000082.json
- Plain text: https://secwatch.observer/filing/0001728117-25-000082.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.